Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 11/20 | 0.60 |
| ▸ | PPARG | P37231 | 10/20 | 0.60 |
| ▸ | PPARD | Q03181 | 2/20 | 0.58 |
| ▸ | IDO1 | P14902 | 1/20 | 0.53 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24037243 | 1.00 | PPARA (0.60) | PPARAPPARGPPARDIDO1SLC17A5 | |
| SCHEMBL8541445 | 1.00 | PPARA (0.60) | PPARAPPARGPPARDIDO1SLC17A5 | |
| SCHEMBL30341699 | 1.00 | PPARA (0.60) | PPARAPPARGPPARDIDO1SLC17A5 | |
| SCHEMBL29746744 | 0.86 | PPARG (0.55) | PPARAPPARGPPARDIDO1SLC17A5 | |
| SCHEMBL8659023 | 0.84 | IDO1 (0.68) | PPARAPPARGPPARDIDO1ACE | |
| SCHEMBL19888241 | 0.84 | SLC17A5 (0.58) | SLC17A5MDM2 | |
| SCHEMBL24037465 | 0.83 | IDO1 (0.48) | IDO1SLC17A5ACEALDH1A1MAPT | |
| SCHEMBL12707588 | 0.82 | SLC17A5 (0.47) | PPARAPPARGPPARDIDO1SLC17A5 | |
| SCHEMBL2399667 | 0.82 | SLC17A5 (0.47) | PPARAPPARGPPARDIDO1SLC17A5 | |
| SCHEMBL9514163 | 0.82 | PPARG (0.51) | PPARAPPARGPPARDIDO1SLC17A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9428524-B2 | Synthetic process for the manufacture of ecteinascidin compounds | PHARMA MAR, S.A. (ES) | 2016-08-30 | — | — | US | disclosed |
| US-9428524-B2 | Synthetic process for the manufacture of ecteinascidin compounds | PHARMA MAR, S.A. (ES) | 2016-08-30 | — | — | US | disclosed |
| EP-2576569-B1 | SYNTHETIC PROCESS FOR THE MANUFACTURE OF ECTEINASCIDIN COMPOUNDS AND INTERMEDIATES | PHARMA MAR SA (ES) | 2015-01-14 | — | — | EP | disclosed |
| US-20130066067-A1 | Synthetic Process for the Manufacture of Ecteinascidin Compounds | PHARMA MAR, S.A. (ES) | 2013-03-14 | — | — | US | disclosed |
| WO-2011147828-A1 | SYNTHETIC PROCESS FOR THE MANUFACTURE OF ECTEINASCIDIN COMPOUNDS | PHARMA MAR, S.A. (ES) | 2011-12-01 | — | — | WO | disclosed |
| US-7420051-B2 | Antitumor agents; microbiocides; antibiotics; forming a 1,4 bridge using a 1-labile, 10-hydroxy, 18-protected hydroxyl, di-6,8-en-5-one fused ring compound. After formation of the 1,4 brige, C-18 protection is removed before spiroamine introduction | PHARMA MAR, S.A. (ES) | 2008-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130066067-A1 | Synthetic Process for the Manufacture of Ecteinascidin Compounds | SERPINH1, ERLIN2, PTMA | PPARA 4397/4885PPARG 4282/4885PPARD 3340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.